CHE.UN-T 0.07 QCOM-Q 2.65 AVGO-Q 4.12 ANET-N 3.27 NTR-T -0.5 T-T -0.29 CGI-T 0.06
Theragenics Corp (TGX-N)

Theragenics Corp (TGX-N)

0.00
-0.00 (0.00%)
2 watching
Icon Financials Financials Icon Analysis Technical Analysis
Interactive Chart
1w 1m 6m 1y
0

Related posts

Nervous markets await Nvidia
PAST TOP PICK

Theragenics Corp(TGX-N)

Dec 06, 2011
(Top Pick Nov 11/10, Up 27.69%) Got tired of management – salaries were too high. They took on debt.
Benj GallanderBenj Gallander
No
Unlock Rating
$1.660

Stock price when the opinion was issued

biotechnology pharmaceutical
PAST TOP PICK

Theragenics Corp(TGX-N)

Nov 03, 2011
(A Top Pick Nov 11/10. Up 28.57%.)
Benj GallanderBenj Gallander
Owned
Unlock Rating
$1.600

Stock price when the opinion was issued

biotechnology pharmaceutical
PAST TOP PICK

Theragenics Corp(TGX-N)

Oct 04, 2011
(Top Pick Nov 11/10, Down 2.30%) out of it personally but fund holds it. Is on their buy list.
Benj GallanderBenj Gallander
Owned
Unlock Rating
$1.250

Stock price when the opinion was issued

biotechnology pharmaceutical
TOP PICK

Theragenics Corp(TGX-N)

Nov 11, 2010
Seeds for cancer patients but also do surgical products. Marginally profitable but revenues are up to record levels at about $80 million. Paying down debt. Would like to see a cleaner balance sheet.
Benj GallanderBenj Gallander
Owned
Unlock Rating
$1.300

Stock price when the opinion was issued

biotechnology pharmaceutical
TOP PICK

Theragenics Corp(TGX-N)

Dec 24, 2007
Cancer therapy. Revenues have grown. Acquired a $10 million company for $30 million, which was questionable. Fairly clean balance sheet.
Benj GallanderBenj Gallander
Owned
Unlock Rating
$3.710

Stock price when the opinion was issued

biotechnology pharmaceutical
WEAK BUY

Theragenics Corp(TGX-N)

Oct 06, 2006
Prostate cancer field. Recently expanded into all kinds of other medical devices, including some four cats and dogs. Made some poor acquisitions. Not happy with management.
Benj GallanderBenj Gallander
Owned
Unlock Rating
$3.070

Stock price when the opinion was issued

biotechnology pharmaceutical
PAST TOP PICK

Theragenics Corp(TGX-N)

Jan 30, 2006
(A Top Pick Sept 6/05. Up 9.5%.) They have cut out their R&D which will save them a lot of money. Acquired another firm which will increase their revenues. They have a beautiful balance sheet. Still have it on their BUY list.
Benj GallanderBenj Gallander
Owned
Unlock Rating
$3.480

Stock price when the opinion was issued

biotechnology pharmaceutical
TOP PICK

Theragenics Corp(TGX-N)

Sep 06, 2005
In the medical products field and treat prostate cancer. Their R&D over the last couple of years has not produced anything. Has a pretty good balance sheet and no debt. BV take a hit because they will be writing off their nuclear research assets. Restructuring and if they just do anything right they will be good as they are dominant in their field.
Ben StadelmannBen Stadelmann
Owned
Unlock Rating
$3.150

Stock price when the opinion was issued

biotechnology pharmaceutical
TOP PICK

Theragenics Corp(TGX-N)

Jan 12, 2005
They have an isotope that is a less invasive way of treating prostrate cancer as opposed to surgery. They're dominant in this field. Had difficulty because of insurance coverage issues. Their competition also has treatment methods, so have competition. Losing money because of more going into R & D. New marketing may help.
Ben StadelmannBen Stadelmann
Owned
Unlock Rating
$3.970

Stock price when the opinion was issued

biotechnology pharmaceutical
PAST TOP PICK

Theragenics Corp(TGX-N)

Nov 09, 2004
(A Top Pick June 14/04. Down 12%.) Have about $30 million in revenues. Operate in the prostrate cancer area which is a growing field. Still on their buy list, but wait until December for tax loss selling. No debt. Good management.
Benj GallanderBenj Gallander
Owned
Unlock Rating
$3.900

Stock price when the opinion was issued

biotechnology pharmaceutical
TOP PICK

Theragenics Corp(TGX-N)

Sep 16, 2004
A demographics play in treatment of prostrate cancer. Dominant in their field. Midicare payment problem seems to be getting worked out. R&D is looking for other cancer treatments.
Ben StadelmannBen Stadelmann
Owned
Unlock Rating
$3.740

Stock price when the opinion was issued

biotechnology pharmaceutical
TOP PICK

Theragenics Corp(TGX-N)

Jul 21, 2004
Benj GallanderBenj Gallander
Owned
Unlock Rating
$4.360

Stock price when the opinion was issued

biotechnology pharmaceutical
TOP PICK

Theragenics Corp(TGX-N)

Jul 16, 2004
Had revenues over $50 million and stock price was over $30. Revenues then dropped to $30 million. Prostate cancer continues to grow demographically and they have a proven product for this. A lot of competition. No long-term debt.
Benj GallanderBenj Gallander
Owned
Unlock Rating
$4.370

Stock price when the opinion was issued

biotechnology pharmaceutical
Showing 1 to 13 of 13 entries
  • «
  • ‹
  • 1
  • ›
  • »

Theragenics Corp(TGX-N) Rating

Ranking : 1 out of 5

Star iconStar empty iconStar empty iconStar empty iconStar empty icon

Bullish - Buy Signals / Votes : 0

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 0

Total Signals / Votes : 0

Stockchase rating for Theragenics Corp is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Theragenics Corp(TGX-N) Frequently Asked Questions

What is Theragenics Corp stock symbol?

Theragenics Corp is a OTC stock, trading under the symbol TGX-N on the (). It is usually referred to as or TGX-N

Is Theragenics Corp a buy or a sell?

In the last year, there was no coverage of Theragenics Corp published on Stockchase.

Is Theragenics Corp a good investment or a top pick?

Theragenics Corp was recommended as a Top Pick by on . Read the latest stock experts ratings for Theragenics Corp.

Why is Theragenics Corp stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Theragenics Corp worth watching?

In the last year, there was no coverage of Theragenics Corp published on Stockchase.

What is Theragenics Corp stock price?

On , Theragenics Corp (TGX-N) stock closed at a price of $.

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

ET-T 0.15$12.2
BNS-T -0.34$77.29
HPS.A-… 3.12$118.69
PPL-T 0.21$50.61
NWH.UN… -0.03$4.81

Today's Top Picks

CHE.UN… 0.07$11.25
QCOM-Q 2.65$161.05
AVGO-Q 4.12$294.3
ANET-N 3.27$117.55
NTR-T -0.5$81.86

Popular Articles

Latest Sell Signals

SWK-N 0.03$73.93
BBY-N 0.35$67.79
HL-N -0.16$5.98
CTRA-N 0.18$23.81
XDV-T -0.124$34.72

Most Recent Experts

Larry Berman CFA, CMT, CTA

Larry Berman CFA, CMT, CTA

ETF Capital Management Inc.

Jamie Murray

Jamie Murray

Murray Wealth Group

Stockchase Insights

Stockchase Insights

5i Research

Jim Cramer - Mad Money

Jim Cramer - Mad Money

CNBC

Brian Madden

Brian Madden

First Avenue Investment Counsel

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: hello@stockchase.com.

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© Stockchase Inc. by Wealthica